Serum determination of IL-1β and IL-1RA in patients with chronic liver diseases

Abstract

Introduction and Objectives: This study aimed to evaluate serum concentration of IL-1β and IL-1RA in subjects with alcoholic liver disease (ALD), chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). Materials and methods: A cross-sectional and multicenter study was carried out, which included alcoholic subjects (OH), alcoholic cirrhosis (CiOH) and alcoholic hepatitis (HA); patients with CHC and NAFLD were compared against subjects without criteria for alcohol drinking habits (CT). IL-1β and IL-1RA were quantified by Multiplex-MERCK©. For statistical analysis SPSS V.22 were used, Mann-Whitney U, p<0.05; values expressed as mean ± standard error. Results: The groups included were: 18 (OH), 25 (CiOH), 14 (HA), 55 (CHC), 22 (NAFLD) and 81 (CT). IL-1β results (pg/mL): 13.8±9.2, OH; 4.4±1.7, CiOH; 3.05±0.05, HA; 7.1±2.3, CHC; 5±2, NAFLD and 3.2±0.1, CT. With differences in HA vs. CHC. For IL-1RA (pg/mL) 83.5±30, OH; 100.4±53.5, CiOH; 85±38.3, HA; 74.4±2, CHC; 316±203, NAFLD and 13.02±4.4, CT. With differences in CHC and NAFLD vs. CT and CiOH vs. CHC. Discussion: IL-1β was 2.3 times increased in HA/CHC, which highlights the effect on exacerbating the inflammatory response in acute over chronic alcohol damage; IL-1RA that inhibits the activities of IL-1β are increase may have protective effects on liver injury. Conclusion: IL-1RA is a cytokine that limits inflammation in liver disease, especially in non-alcoholic fatty liver disease, alcoholic cirrhosis and chronic hepatitis C. Funding: This work was partially financed by CONACyT SALUD-2016-272579 and PAPIIT- UNAM TA200515 Declaration of interest: The authors declare no potential conflicts of interest.